Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update
Journal
Hepatology International
Journal Volume
2
Journal Issue
3
Pages
263-283
Date Issued
2008
Author(s)
Abstract
Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included. ? Asian Pacific Association for the Study of the Liver 2008.
Subjects
Adefovir; Chronic hepatitis B; Entecavir; Hepatitis B virus (HBV); Hepatocellular carcinoma; Interferon-α; Lamivudine; Liver cirrhosis; Pegylated interferon; Telbivudine
SDGs
Other Subjects
adefovir dipivoxil; alpha interferon; antivirus agent; clevudine; corticosteroid; entecavir; hepatitis B antibody; hepatitis B surface antigen; hepatitis B vaccine; hepatitis B(e) antigen; interferon; lamivudine; nucleoside derivative; peginterferon; peginterferon alpha; peginterferon alpha2a; peginterferon alpha2b; placebo; telbivudine; tenofovir disoproxil; thymosin alpha1; alanine aminotransferase blood level; antiviral activity; aspartate aminotransferase blood level; clinical trial; combination chemotherapy; creatinine blood level; decompensated liver cirrhosis; delta agent hepatitis; depression; disease course; drug bioavailability; drug contraindication; drug dose comparison; drug efficacy; drug indication; drug megadose; drug response; drug safety; drug substitution; drug tolerability; drug withdrawal; fatigue; hepatitis B; hepatitis C; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; immunomodulation; immunosuppressive treatment; influenza; kidney failure; laboratory test; liver cirrhosis; liver transplantation; low drug dose; monotherapy; multiple cycle treatment; myopathy; nephrotoxicity; neutropenia; pathogenesis; pregnancy; priority journal; review; seroconversion; side effect; thrombocytopenia; unspecified side effect; virus load; virus reactivation; virus replication
Publisher
Springer New York
Type
review